Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.
Treatment resistant depression (TRD) represents approximately 20% of all individuals receiving care for major depressive disorder. The opioidergic system is identified as a novel target which hitherto has not been sufficiently investigated in adults with TRD. The combination product buprenorphine + samidorphan is an opioid modulatory agent which has demonstrated replicated evidence of efficacy in TRD without abuse liability. Areas covered: Databases Pubmed, Google Scholar and clinicaltrials.gov were searched from inception through December 2017 for clinical trial information, pharmacokinetics, and pharmacodynamics of buprenorphine + samidorphan. Herein we provide a summary of the available information. Eight clinical trials were identified for inclusion, of the eight trials, five trials had available results and are included in detail in our review. Expert opinion: Buprenorphine + samidorphan has demonstrated efficacy in TRD. Extant evidence surrounding the safety and tolerability profile of buprenorphine + samidorphan does not identify any significant safety concerns. Additional studies are needed in order to assess the long-term safety and efficacy of this product.
['Ragguett|Renee-Marie|RM|', 'Rong|Carola|C|http://orcid.org/0000-0002-1408-4968', 'Rosenblat|Joshua D|JD|', 'Ho|Roger C|RC|', 'McIntyre|Roger S|RS|']
D000928:Antidepressive Agents D002047:Buprenorphine D003865:Depressive Disorder, Major D061218:Depressive Disorder, Treatment-Resistant D004338:Drug Combinations D006801:Humans D009271:Naltrexone D016896:Treatment Outcome
buprenorphine + samidorphan Major depressive disorder treatment resistant depression opioidergic system opioid